Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: rheuma plus 2/2017

01.06.2017 | JIA

Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis

verfasst von: Dr. A. Hospach, J. M. Rühlmann, F. Weller-Heinemann

Erschienen in: rheuma plus | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Die Polyarthritis ist mit ca. 20 % die dritthäufigste Verlaufsform der juvenilen idiopathischen Arthritis (JIA). Die Polyarthritis ist aber Ursache eines bedeutenden Teils der Krankheitslast und der Langzeitprobleme der JIA. Etablierte Therapieformen mit Steroiden und konventionellen „disease-modifying anti-rheumatic drugs“ (DMARDs) sind in den vergangenen Jahren insbesondere durch die Zulassung neuer Biologika erheblich erweitert worden. Die aktuellen Therapiemöglichkeiten werden hier dargestellt.
Literatur
1.
Zurück zum Zitat Petty RE et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392 PubMed Petty RE et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392 PubMed
2.
Zurück zum Zitat Huppertz HI (2011) New criteria for the classification of rheumatoid arthritis: significance for child and adolescent rheumatology? Z Rheumatol 70(5):372–374 CrossRefPubMed Huppertz HI (2011) New criteria for the classification of rheumatoid arthritis: significance for child and adolescent rheumatology? Z Rheumatol 70(5):372–374 CrossRefPubMed
3.
Zurück zum Zitat Adib N et al (2008) Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 47(7):991–995 CrossRef Adib N et al (2008) Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 47(7):991–995 CrossRef
4.
Zurück zum Zitat Oen KG, Cheang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26(3):575–591 CrossRefPubMed Oen KG, Cheang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26(3):575–591 CrossRefPubMed
5.
Zurück zum Zitat Greenwald AG et al (2013) Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group? Clin Exp Rheumatol 31(4):645–652 PubMed Greenwald AG et al (2013) Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group? Clin Exp Rheumatol 31(4):645–652 PubMed
6.
Zurück zum Zitat Saurenmann RK et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984 CrossRefPubMed Saurenmann RK et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984 CrossRefPubMed
7.
Zurück zum Zitat Twilt M et al (2008) Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Rheum 59(4):546–552 CrossRefPubMed Twilt M et al (2008) Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Rheum 59(4):546–552 CrossRefPubMed
8.
Zurück zum Zitat Hospach T et al (2014) Cervical spine involvement in patients with juvenile idiopathic arthritis – MRI follow-up study. Pediatr Rheumatol Online J 12:9 CrossRefPubMedPubMedCentral Hospach T et al (2014) Cervical spine involvement in patients with juvenile idiopathic arthritis – MRI follow-up study. Pediatr Rheumatol Online J 12:9 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Elhai M et al (2013) Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 52(2):267–275 CrossRef Elhai M et al (2013) Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 52(2):267–275 CrossRef
10.
Zurück zum Zitat Ringold S et al (2009) Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 48(8):972–977 CrossRef Ringold S et al (2009) Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 48(8):972–977 CrossRef
11.
Zurück zum Zitat Ansell BM (1983) Juvenile chronic arthritis with persistently positive tests for rheumatoid factor (sero-positive juvenile rheumatoid arthritis). Ann Pediatr (Paris) 30(8):545–550 Ansell BM (1983) Juvenile chronic arthritis with persistently positive tests for rheumatoid factor (sero-positive juvenile rheumatoid arthritis). Ann Pediatr (Paris) 30(8):545–550
12.
Zurück zum Zitat Schanberg LE et al (2005) Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum 52(4):1196–1204 CrossRefPubMed Schanberg LE et al (2005) Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum 52(4):1196–1204 CrossRefPubMed
13.
Zurück zum Zitat Sabri K et al (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12(6):539–545 CrossRefPubMed Sabri K et al (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12(6):539–545 CrossRefPubMed
14.
Zurück zum Zitat Kotaniemi K et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108(11):2071–2075 CrossRefPubMed Kotaniemi K et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108(11):2071–2075 CrossRefPubMed
15.
Zurück zum Zitat Heiligenhaus A et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019 CrossRef Heiligenhaus A et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019 CrossRef
16.
Zurück zum Zitat Angeles-Han ST et al (2013) Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 40(12):2088–2096 CrossRefPubMedPubMedCentral Angeles-Han ST et al (2013) Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 40(12):2088–2096 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Heiligenhaus A et al (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180–191 CrossRefPubMed Heiligenhaus A et al (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180–191 CrossRefPubMed
18.
Zurück zum Zitat Schmeling H et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66(9):2580–2589 CrossRefPubMed Schmeling H et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66(9):2580–2589 CrossRefPubMed
19.
Zurück zum Zitat Oen K et al (2003) Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 30(3):585–593 PubMed Oen K et al (2003) Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 30(3):585–593 PubMed
20.
Zurück zum Zitat Minden K et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407–1415 CrossRef Minden K et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407–1415 CrossRef
21.
Zurück zum Zitat Huppertz HI, Lehmann HW (2014) Evidence of treatment of chronic inflammation in childhood and adolescence with biologics. Z Rheumatol 73(10):907–916 CrossRefPubMed Huppertz HI, Lehmann HW (2014) Evidence of treatment of chronic inflammation in childhood and adolescence with biologics. Z Rheumatol 73(10):907–916 CrossRefPubMed
22.
Zurück zum Zitat Beukelman T, Brunner H et al (2016) Chapter 6. In: Petty R, Laxer R (Hrsg) Textbook of pediatric rheumatology. Elsevier, Philadelphia Beukelman T, Brunner H et al (2016) Chapter 6. In: Petty R, Laxer R (Hrsg) Textbook of pediatric rheumatology. Elsevier, Philadelphia
23.
Zurück zum Zitat Guzman J et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74(10):1854–1860 CrossRefPubMed Guzman J et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74(10):1854–1860 CrossRefPubMed
24.
Zurück zum Zitat Dueckers G et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193 CrossRefPubMed Dueckers G et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193 CrossRefPubMed
25.
Zurück zum Zitat Beukelman T et al (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465–482 CrossRef Beukelman T et al (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465–482 CrossRef
26.
Zurück zum Zitat Niehues T (2011) Leitlinien AWMF Register Nr. 027/020 Niehues T (2011) Leitlinien AWMF Register Nr. 027/020
27.
Zurück zum Zitat Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671–1684 CrossRefPubMed Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671–1684 CrossRefPubMed
28.
Zurück zum Zitat Beukelman T et al (2012) Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 39(9):1867–1874 CrossRefPubMedPubMedCentral Beukelman T et al (2012) Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 39(9):1867–1874 CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Giannini EH et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 326(16):1043–1049 CrossRefPubMed Giannini EH et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 326(16):1043–1049 CrossRefPubMed
30.
Zurück zum Zitat Alsufyani K et al (2004) The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31(1):179–182 PubMed Alsufyani K et al (2004) The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31(1):179–182 PubMed
31.
Zurück zum Zitat Ruperto N et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201 CrossRefPubMed Ruperto N et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201 CrossRefPubMed
32.
Zurück zum Zitat Céspedes-Cruz A et al (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67(3):309–314 CrossRefPubMed Céspedes-Cruz A et al (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67(3):309–314 CrossRefPubMed
33.
Zurück zum Zitat Albers HM (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61:46–51 CrossRefPubMed Albers HM (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61:46–51 CrossRefPubMed
34.
Zurück zum Zitat Savolainen HA et al (1997) Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 24(12):2444–2450 PubMed Savolainen HA et al (1997) Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 24(12):2444–2450 PubMed
35.
Zurück zum Zitat Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123 PubMed Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123 PubMed
36.
Zurück zum Zitat Curtis JR et al (2013) Clinical response within 12 weeks as a predictor of future low disease activity in early RA patients: results from the TEAR Trial. J Rheumatol 40(5):572–578 CrossRefPubMedPubMedCentral Curtis JR et al (2013) Clinical response within 12 weeks as a predictor of future low disease activity in early RA patients: results from the TEAR Trial. J Rheumatol 40(5):572–578 CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Silverman E et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666 CrossRefPubMed Silverman E et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666 CrossRefPubMed
38.
Zurück zum Zitat Ringold S et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072 CrossRef Ringold S et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072 CrossRef
39.
Zurück zum Zitat Breit W et al (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702 PubMed Breit W et al (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702 PubMed
40.
Zurück zum Zitat Huppertz HI et al (2011) Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 31(10):1259–1262 CrossRefPubMedPubMedCentral Huppertz HI et al (2011) Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 31(10):1259–1262 CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Huppertz HI (2011) Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al. Arthritis Care Res (Hoboken) 63(9):1354–1355 (author reply 1355–1356) CrossRef Huppertz HI (2011) Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al. Arthritis Care Res (Hoboken) 63(9):1354–1355 (author reply 1355–1356) CrossRef
42.
Zurück zum Zitat Lovell DJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769 CrossRefPubMed Lovell DJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769 CrossRefPubMed
43.
Zurück zum Zitat Lovell DJ et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496–1504 CrossRefPubMed Lovell DJ et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496–1504 CrossRefPubMed
44.
Zurück zum Zitat Papsdorf V, Horneff G (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50(1):214–221 CrossRef Papsdorf V, Horneff G (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50(1):214–221 CrossRef
45.
Zurück zum Zitat Nielsen S et al (2008) Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 26(4):688–692 PubMed Nielsen S et al (2008) Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 26(4):688–692 PubMed
46.
Zurück zum Zitat Horneff G et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525 CrossRefPubMed Horneff G et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525 CrossRefPubMed
47.
Zurück zum Zitat Beukelman T et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780 CrossRefPubMedPubMedCentral Beukelman T et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780 CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Toussi SS et al (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 57(9):1318–1330 CrossRefPubMedPubMedCentral Toussi SS et al (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 57(9):1318–1330 CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat McCroskery P et al (2010) Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 14(8):18–26 CrossRef McCroskery P et al (2010) Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 14(8):18–26 CrossRef
50.
51.
Zurück zum Zitat Simard JF et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776–3782 CrossRefPubMed Simard JF et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776–3782 CrossRefPubMed
52.
Zurück zum Zitat Lovell DJ et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820 CrossRefPubMed Lovell DJ et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820 CrossRefPubMed
53.
Zurück zum Zitat Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, doubleblind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191–S192 CrossRef Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, doubleblind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191–S192 CrossRef
54.
Zurück zum Zitat Ruperto N et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391 CrossRefPubMed Ruperto N et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391 CrossRefPubMed
55.
Zurück zum Zitat Brunner HI et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117 CrossRefPubMed Brunner HI et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117 CrossRefPubMed
56.
Zurück zum Zitat Holzinger D et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980 CrossRefPubMed Holzinger D et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980 CrossRefPubMed
57.
Zurück zum Zitat Swart JF, de Roock S, Wulffraat NM (2013) What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 15(3):213 CrossRefPubMedPubMedCentral Swart JF, de Roock S, Wulffraat NM (2013) What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 15(3):213 CrossRefPubMedPubMedCentral
Metadaten
Titel
Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis
verfasst von
Dr. A. Hospach
J. M. Rühlmann
F. Weller-Heinemann
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 2/2017
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-016-0090-2

Weitere Artikel der Ausgabe 2/2017

rheuma plus 2/2017 Zur Ausgabe